Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,621 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, Creese B, Loughlin P, Bannister C, Burns A, Win SN, Walker Z; MAIN-AD investigators. Ballard C, et al. Among authors: thomas a. J Am Med Dir Assoc. 2015 Apr;16(4):316-22. doi: 10.1016/j.jamda.2014.11.002. Epub 2014 Dec 15. J Am Med Dir Assoc. 2015. PMID: 25523285 Clinical Trial.
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.
Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, O'Brien JT. Ballard CG, et al. Among authors: thomas a. J Clin Psychiatry. 2004 Jan;65(1):114-9. doi: 10.4088/jcp.v65n0120. J Clin Psychiatry. 2004. PMID: 14744180 Clinical Trial.
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. Ballard C, et al. Among authors: thomas a. BMJ. 2005 Apr 16;330(7496):874. doi: 10.1136/bmj.38369.459988.8F. Epub 2005 Feb 18. BMJ. 2005. PMID: 15722369 Free PMC article. Clinical Trial.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Burns A, O'Brien J; BAP Dementia Consensus group; Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Burns A, et al. Among authors: thomas a. J Psychopharmacol. 2006 Nov;20(6):732-55. doi: 10.1177/0269881106068299. J Psychopharmacol. 2006. PMID: 17060346 Review.
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A. Banerjee S, et al. Among authors: thomas a. Lancet. 2011 Jul 30;378(9789):403-11. doi: 10.1016/S0140-6736(11)60830-1. Epub 2011 Jul 19. Lancet. 2011. PMID: 21764118 Review.
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.
Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, Bentham P, Burns A, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Banerjee S. Romeo R, et al. Among authors: thomas a. Br J Psychiatry. 2013 Feb;202:121-8. doi: 10.1192/bjp.bp.112.115212. Epub 2012 Dec 20. Br J Psychiatry. 2013. PMID: 23258767 Free article. Clinical Trial.
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A. Banerjee S, et al. Among authors: thomas a. Health Technol Assess. 2013 Feb;17(7):1-166. doi: 10.3310/hta17070. Health Technol Assess. 2013. PMID: 23438937 Free PMC article. Clinical Trial.
9,621 results